Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | HRH2 | P25021 | 1/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | DRD3 | P35462 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339642 | 1.00 | SLC6A4 (0.75) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL2006721 | 1.00 | SLC6A4 (0.75) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL7688733 | 0.99 | SLC6A4 (0.73) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL30681653 | 0.90 | SLC6A4 (0.69) | SLC6A4 | |
| SCHEMBL1120 | 0.90 | SLC6A4 (0.75) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL143594 | 0.88 | SLC6A4 (0.73) | SLC6A4 | |
| SCHEMBL141623 | 0.88 | SLC6A4 (0.83) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL29582298 | 0.85 | SLC6A4 (0.56) | SLC6A4NPC1SLC22A1ALDH1A1CHRM2 | |
| SCHEMBL2872832 | 0.85 | SLC6A4 (0.68) | SLC6A4 | |
| SCHEMBL3408141 | 0.85 | SLC6A4 (0.57) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251410-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMA GLOBAL FZE (AE) | 2011-10-13 | — | — | US | disclosed |
| US-7989645-B2 | Escitalopram with chiral purity greater than 99.8% obtained in more than 50% yield; without chiral chromatographic separation | SUN PHARMA GLOBAL FZE (AE) | 2011-08-02 | — | — | US | disclosed |
| US-7964742-B2 | including preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile intermediate by cyclization of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)benzonitrile in the presence of a base | SUN PHARMA GLOBAL FZE (AE) | 2011-06-21 | — | — | US | disclosed |
| US-20100249437-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMA GLOBAL FZE (AE) | 2010-09-30 | — | — | US | disclosed |
| US-7790935-B2 | Process for preparation of citalopram and enantiomers | SUN PHARMA GLOBAL FZE (AE) | 2010-09-07 | — | — | US | disclosed |
| EP-2141156-A1 | Process for Preparation of Citalopram and Enantiomers | Sun Pharma Global FZE (AE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090326249-A1 | Process for Preparation of Citalopram and Enantiomers | SUN PHARMA GLOBAL FZE (AE) | 2009-12-31 | — | — | US | disclosed |
| US-20080177096-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251410-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | SLC6A4 142/4885NPC1 901/4885SLC22A1 1861/4885 |
| US-20090326249-A1 | Process for Preparation of Citalopram and Enantiomers | HTR1F, CYP2F1, CYP4F11 | SLC6A4 71/4885NPC1 1448/4885SLC22A1 1550/4885 |
| US-20100249437-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | SLC6A4 71/4885NPC1 1448/4885SLC22A1 1550/4885 |
| US-20080177096-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | SLC6A4 142/4885NPC1 901/4885SLC22A1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.